Navigation Links
Can disclosure hurt the translation of research?
Date:9/19/2012

Boston, MA All major clinical trials now include disclosures detailing who funded the study to ensure transparency. However, is it possible that this transparency is actually hurting research? One might assume that the methodological rigor of the study matters to physicians more than the disclosure. However, in a new study, researchers at Brigham and Women's Hospital (BWH) have found that pharmaceutical industry sponsorship of a research study negatively influences physicians' perceptions of the study and their willingness to believe and act on the research findings. This study will be published in the September 20, 2012 issue of the New England Journal of Medicine (NEJM).

"We found that physicians downgraded their perceptions of industry funded research similarly for high-quality studies and low-quality studies," explained Aaron Kesselheim, MD, JD, assistant professor of medicine in the Division of Pharmacoepidemiology and Pharmacoeconomics at BWH, and principal investigator of this study.

The research team presented abstracts describing hypothetical clinical trials of three fictional, but potentially useful, new drugs to a national sample of board-certified internal medicine physicians. Each abstract was randomized to demonstrate high, medium, or low methodological rigor and randomized to report one of three disclosure variables: funding from a pharmaceutical company, funding by the National Institutes of Health (NIH), or no disclosure listed. The investigators then assessed physicians' impressions of the trials' rigor, their confidence in the results, and their willingness to prescribe the drugs.

"We found clear associations between the funding disclosure variations and physicians' perceptions of a trial's rigor and results," explained Dr. Kesselheim.

The results showed that physicians downgraded the credibility of industry-funded trials when compared with the same trials that had no funding listed, and to an even greater extent when compared with the same trials characterized as having NIH funding. The authors attributed these results to high-profile instances of unethical behavior by pharmaceutical companies sponsoring clinical research in the past decade.

Researchers emphasize that these findings have important implications. The pharmaceutical industry funds a substantial portion of clinical research, and a key determinant of the impact of a trial should be its methodological rigor, not its funding source, Dr. Kesselheim and his co-authors argue.

"While there is good reason to be extra vigilant about industry-funded research, if physicians are reluctant to trust all such research, this could hinder the translation of even high-quality industry-funded research into practice. Strategies such as greater transparency and independent review of trial data could be pursued to try to change such attitudes among physicians," Dr. Kesselheim suggested.


'/>"/>

Contact: Jessica Maki
jmaki3@partners.org
617-534-1603
Brigham and Women's Hospital
Source:Eurekalert

Related medicine news :

1. Study finds non-disclosure of HIV serostatus common among India female sex workers
2. New federal disclosure law may have little impact on drugs prescribed
3. Penn Translational Medicine Institute to hold 7th Annual Symposium
4. Translation of research into practice for post-stroke care goes national
5. Weill Cornell awarded $1.8 million for translational blood cancer research
6. SU2C, Dutch Cancer Society announce new International Translational Cancer Research Grant recipients
7. U-Ms Taubman Institute awards inaugural $100,000 translational medical research prize
8. TMC institutions get $20 million renewal grant for translational medicine center
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... ... February 23, 2017 , ... ... Justice jointly issued a letter to withdraw previous guidance issued by ... gender identity. The guidance issued in May 2016 by the Obama Administration came ...
(Date:2/23/2017)... (PRWEB) , ... February 23, 2017 , ... ... outlet with a clinician-based audience, will be participating in Rare Disease Day events, ... Washington, D.C. In addition, Rare Disease Report, a website, weekly e-newsletter and quarterly ...
(Date:2/23/2017)... ... , ... Hamlin Dental Group and Dr. Hamid Reza, dentist in North ... month of February, patients who visit Hamlin Dental Group will receive a ticket for ... at the Cheesecake Factory. , Tickets are available for routine dental visits and ...
(Date:2/23/2017)... ... February 23, 2017 , ... On April 13, ... symposium on “Doping in Sport: How the Culture Might Change,” in ... LLP. The symposium will be held at Pepperdine University in Malibu, California. , ...
(Date:2/23/2017)... ... February 23, 2017 , ... ERT, a global data and ... Premier Research, a leading clinical development service provider, has selected ERT’s Trial Oversight ... due in part to an array of circumstances including the use of multiple ...
Breaking Medicine News(10 mins):
(Date:2/23/2017)... -- Genesis Healthcare Services has merged with Hospice Cloud, a ... Bill Monast , President and CEO of Hospice Cloud ... , executives with Home Health Depot, Inc., the parent ... This acquisition helps Hospice Cloud maintain its position as ... equipment (DME) solutions for the hospice industry. Nathan ...
(Date:2/23/2017)... , Feb. 23, 2017  Cogentix Medical, Inc. ... and markets innovative proprietary products for the urology market, ... fiscal year ended December 31, 2016 before the market ... The Company will host a conference call and webcast ... Thursday, March 9, 2017 at 11:00 a.m. Eastern Time ...
(Date:2/23/2017)... REDWOOD CITY, Calif., Feb. 23, 2017 Nevro Corp. ... innovative evidence-based solutions for the treatment of chronic pain, today ... ended December 31, 2016. 2016 Accomplishment & ... the full year 2016, an increase of 228% as reported, ... million for 2016, an increase of 612% over the prior ...
Breaking Medicine Technology: